Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome
Identifieur interne : 002215 ( Main/Corpus ); précédent : 002214; suivant : 002216Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome
Auteurs : Marc Dubuc ; Teresa Kus ; Maria Aurora Campa ; Chantal Lambert ; Michael Rosengarten ; Mohammad ShenasaSource :
- American Heart Journal [ 0002-8703 ] ; 1988.
Abstract
The electrophysiologic effects of intravenous propafenone were studied in 15 consecutive patients with accessory pathways. Thirteen patients had sustained orthodromic supraventricular tachycardia induced during baseline study, and two patients needed isoproterenol to render it sustained. In all except one patient, propafenone, 2 mg/kg given intravenously over a 10-minute period, was successful converting the arrthythmia to sinus rhythm. Atrial fibrillation was inducible in 10 patients before propafenone, but was no longer inducible in seven of these patients after the drug. The HV interval (23 ± 20 to 41 ± 25 msec) and the anterograde (310 ± 96 to 509 ± 145 msec) and retrograde (256 ± 30 to 334 ± 105 msec) effective refractory periods of the bypass tract were all significantly prolonged after the drug. The pacing cycle length that produced conduction block over the bypass tract anterogradely (319 ± 126 to 446 ± 150 msec) and retrogradely (272 ± 25 to 360 ± 97 msec) was also increased. During orthodromic tachycardia, propafenone increased conduction time in both the anterograde and retrograde limbs of the tachycardia. Tachycardia terminated in the retrograde limb in 64% of the patients. We conclude that propafenone is very effective in terminating orthodromic tachycardia when given intravenously and that it should be considered in patients initially seen with atrial fibrillation and short refractory periods.
Url:
DOI: 10.1016/0002-8703(89)90781-3
Links to Exploration step
ISTEX:9E7DD0E4258275C9FE85B6F1BE09ECEF9DE59EB6Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome</title><author><name sortKey="Dubuc, Marc" sort="Dubuc, Marc" uniqKey="Dubuc M" first="Marc" last="Dubuc">Marc Dubuc</name><affiliation><mods:affiliation>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</mods:affiliation></affiliation></author><author><name sortKey="Kus, Teresa" sort="Kus, Teresa" uniqKey="Kus T" first="Teresa" last="Kus">Teresa Kus</name><affiliation><mods:affiliation>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>McGill University Montreal, Quebec, Canada</mods:affiliation></affiliation></author><author><name sortKey="Campa, Maria Aurora" sort="Campa, Maria Aurora" uniqKey="Campa M" first="Maria Aurora" last="Campa">Maria Aurora Campa</name><affiliation><mods:affiliation>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>McGill University Montreal, Quebec, Canada</mods:affiliation></affiliation></author><author><name sortKey="Lambert, Chantal" sort="Lambert, Chantal" uniqKey="Lambert C" first="Chantal" last="Lambert">Chantal Lambert</name><affiliation><mods:affiliation>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>McGill University Montreal, Quebec, Canada</mods:affiliation></affiliation></author><author><name sortKey="Rosengarten, Michael" sort="Rosengarten, Michael" uniqKey="Rosengarten M" first="Michael" last="Rosengarten">Michael Rosengarten</name><affiliation><mods:affiliation>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>McGill University Montreal, Quebec, Canada</mods:affiliation></affiliation></author><author><name sortKey="Shenasa, Mohammad" sort="Shenasa, Mohammad" uniqKey="Shenasa M" first="Mohammad" last="Shenasa">Mohammad Shenasa</name><affiliation><mods:affiliation>Reprint requests: Mohammad Shenasa, MD, PhD, Research Center, Sacré-Coeur Hospital, 5400, Gouin West, Montreal, Quebec, Canada H4J 1C5.</mods:affiliation></affiliation><affiliation><mods:affiliation>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>McGill University Montreal, Quebec, Canada</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9E7DD0E4258275C9FE85B6F1BE09ECEF9DE59EB6</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1016/0002-8703(89)90781-3</idno><idno type="url">https://api.istex.fr/document/9E7DD0E4258275C9FE85B6F1BE09ECEF9DE59EB6/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002215</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome</title><author><name sortKey="Dubuc, Marc" sort="Dubuc, Marc" uniqKey="Dubuc M" first="Marc" last="Dubuc">Marc Dubuc</name><affiliation><mods:affiliation>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</mods:affiliation></affiliation></author><author><name sortKey="Kus, Teresa" sort="Kus, Teresa" uniqKey="Kus T" first="Teresa" last="Kus">Teresa Kus</name><affiliation><mods:affiliation>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>McGill University Montreal, Quebec, Canada</mods:affiliation></affiliation></author><author><name sortKey="Campa, Maria Aurora" sort="Campa, Maria Aurora" uniqKey="Campa M" first="Maria Aurora" last="Campa">Maria Aurora Campa</name><affiliation><mods:affiliation>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>McGill University Montreal, Quebec, Canada</mods:affiliation></affiliation></author><author><name sortKey="Lambert, Chantal" sort="Lambert, Chantal" uniqKey="Lambert C" first="Chantal" last="Lambert">Chantal Lambert</name><affiliation><mods:affiliation>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>McGill University Montreal, Quebec, Canada</mods:affiliation></affiliation></author><author><name sortKey="Rosengarten, Michael" sort="Rosengarten, Michael" uniqKey="Rosengarten M" first="Michael" last="Rosengarten">Michael Rosengarten</name><affiliation><mods:affiliation>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>McGill University Montreal, Quebec, Canada</mods:affiliation></affiliation></author><author><name sortKey="Shenasa, Mohammad" sort="Shenasa, Mohammad" uniqKey="Shenasa M" first="Mohammad" last="Shenasa">Mohammad Shenasa</name><affiliation><mods:affiliation>Reprint requests: Mohammad Shenasa, MD, PhD, Research Center, Sacré-Coeur Hospital, 5400, Gouin West, Montreal, Quebec, Canada H4J 1C5.</mods:affiliation></affiliation><affiliation><mods:affiliation>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>McGill University Montreal, Quebec, Canada</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">American Heart Journal</title><title level="j" type="abbrev">YMHJ</title><idno type="ISSN">0002-8703</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1988">1988</date><biblScope unit="volume">117</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="370">370</biblScope><biblScope unit="page" to="376">376</biblScope></imprint><idno type="ISSN">0002-8703</idno></series><idno type="istex">9E7DD0E4258275C9FE85B6F1BE09ECEF9DE59EB6</idno><idno type="DOI">10.1016/0002-8703(89)90781-3</idno><idno type="PII">0002-8703(89)90781-3</idno><idno type="ArticleID">89907813</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0002-8703</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The electrophysiologic effects of intravenous propafenone were studied in 15 consecutive patients with accessory pathways. Thirteen patients had sustained orthodromic supraventricular tachycardia induced during baseline study, and two patients needed isoproterenol to render it sustained. In all except one patient, propafenone, 2 mg/kg given intravenously over a 10-minute period, was successful converting the arrthythmia to sinus rhythm. Atrial fibrillation was inducible in 10 patients before propafenone, but was no longer inducible in seven of these patients after the drug. The HV interval (23 ± 20 to 41 ± 25 msec) and the anterograde (310 ± 96 to 509 ± 145 msec) and retrograde (256 ± 30 to 334 ± 105 msec) effective refractory periods of the bypass tract were all significantly prolonged after the drug. The pacing cycle length that produced conduction block over the bypass tract anterogradely (319 ± 126 to 446 ± 150 msec) and retrogradely (272 ± 25 to 360 ± 97 msec) was also increased. During orthodromic tachycardia, propafenone increased conduction time in both the anterograde and retrograde limbs of the tachycardia. Tachycardia terminated in the retrograde limb in 64% of the patients. We conclude that propafenone is very effective in terminating orthodromic tachycardia when given intravenously and that it should be considered in patients initially seen with atrial fibrillation and short refractory periods.</div></front></TEI><istex><corpusName>elsevier</corpusName><author><json:item><name>Marc Dubuc MD</name><affiliations><json:string>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</json:string><json:string>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</json:string><json:string>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</json:string><json:string>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</json:string></affiliations></json:item><json:item><name>Teresa Kus MD, PhD</name><affiliations><json:string>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</json:string><json:string>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</json:string><json:string>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</json:string><json:string>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</json:string><json:string>McGill University Montreal, Quebec, Canada</json:string></affiliations></json:item><json:item><name>Maria Aurora Campa MD</name><affiliations><json:string>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</json:string><json:string>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</json:string><json:string>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</json:string><json:string>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</json:string><json:string>McGill University Montreal, Quebec, Canada</json:string></affiliations></json:item><json:item><name>Chantal Lambert PhD</name><affiliations><json:string>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</json:string><json:string>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</json:string><json:string>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</json:string><json:string>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</json:string><json:string>McGill University Montreal, Quebec, Canada</json:string></affiliations></json:item><json:item><name>Michael Rosengarten MD</name><affiliations><json:string>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</json:string><json:string>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</json:string><json:string>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</json:string><json:string>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</json:string><json:string>McGill University Montreal, Quebec, Canada</json:string></affiliations></json:item><json:item><name>Mohammad Shenasa MD, PhD</name><affiliations><json:string>Reprint requests: Mohammad Shenasa, MD, PhD, Research Center, Sacré-Coeur Hospital, 5400, Gouin West, Montreal, Quebec, Canada H4J 1C5.</json:string><json:string>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</json:string><json:string>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</json:string><json:string>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</json:string><json:string>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</json:string><json:string>McGill University Montreal, Quebec, Canada</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Clinical investigations</value></json:item></subject><articleId><json:string>89907813</json:string></articleId><language><json:string>eng</json:string></language><abstract>The electrophysiologic effects of intravenous propafenone were studied in 15 consecutive patients with accessory pathways. Thirteen patients had sustained orthodromic supraventricular tachycardia induced during baseline study, and two patients needed isoproterenol to render it sustained. In all except one patient, propafenone, 2 mg/kg given intravenously over a 10-minute period, was successful converting the arrthythmia to sinus rhythm. Atrial fibrillation was inducible in 10 patients before propafenone, but was no longer inducible in seven of these patients after the drug. The HV interval (23 ± 20 to 41 ± 25 msec) and the anterograde (310 ± 96 to 509 ± 145 msec) and retrograde (256 ± 30 to 334 ± 105 msec) effective refractory periods of the bypass tract were all significantly prolonged after the drug. The pacing cycle length that produced conduction block over the bypass tract anterogradely (319 ± 126 to 446 ± 150 msec) and retrogradely (272 ± 25 to 360 ± 97 msec) was also increased. During orthodromic tachycardia, propafenone increased conduction time in both the anterograde and retrograde limbs of the tachycardia. Tachycardia terminated in the retrograde limb in 64% of the patients. We conclude that propafenone is very effective in terminating orthodromic tachycardia when given intravenously and that it should be considered in patients initially seen with atrial fibrillation and short refractory periods.</abstract><qualityIndicators><score>5.556</score><pdfVersion>1.3</pdfVersion><pdfPageSize>591 x 806 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>1</keywordCount><abstractCharCount>1430</abstractCharCount><pdfWordCount>2940</pdfWordCount><pdfCharCount>21556</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>218</abstractWordCount></qualityIndicators><title>Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome</title><pii><json:string>0002-8703(89)90781-3</json:string></pii><genre><json:string>research-article</json:string></genre><host><volume>117</volume><pii><json:string>S0002-8703(00)X0579-0</json:string></pii><pages><last>376</last><first>370</first></pages><issn><json:string>0002-8703</json:string></issn><issue>2</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><title>American Heart Journal</title><publicationDate>1989</publicationDate></host><publicationDate>1988</publicationDate><copyrightDate>1989</copyrightDate><doi><json:string>10.1016/0002-8703(89)90781-3</json:string></doi><id>9E7DD0E4258275C9FE85B6F1BE09ECEF9DE59EB6</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/9E7DD0E4258275C9FE85B6F1BE09ECEF9DE59EB6/fulltext/pdf</uri></json:item><json:item><original>true</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/9E7DD0E4258275C9FE85B6F1BE09ECEF9DE59EB6/fulltext/txt</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/9E7DD0E4258275C9FE85B6F1BE09ECEF9DE59EB6/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/9E7DD0E4258275C9FE85B6F1BE09ECEF9DE59EB6/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>ELSEVIER</p></availability><date>1989</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome</title><author><persName><forename type="first">Marc</forename><surname>Dubuc</surname></persName><roleName type="degree">MD</roleName><affiliation>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</affiliation><affiliation>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</affiliation><affiliation>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</affiliation><affiliation>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</affiliation></author><author><persName><forename type="first">Teresa</forename><surname>Kus</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</affiliation><affiliation>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</affiliation><affiliation>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</affiliation><affiliation>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</affiliation><affiliation>McGill University Montreal, Quebec, Canada</affiliation></author><author><persName><forename type="first">Maria Aurora</forename><surname>Campa</surname></persName><roleName type="degree">MD</roleName><affiliation>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</affiliation><affiliation>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</affiliation><affiliation>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</affiliation><affiliation>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</affiliation><affiliation>McGill University Montreal, Quebec, Canada</affiliation></author><author><persName><forename type="first">Chantal</forename><surname>Lambert</surname></persName><roleName type="degree">PhD</roleName><affiliation>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</affiliation><affiliation>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</affiliation><affiliation>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</affiliation><affiliation>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</affiliation><affiliation>McGill University Montreal, Quebec, Canada</affiliation></author><author><persName><forename type="first">Michael</forename><surname>Rosengarten</surname></persName><roleName type="degree">MD</roleName><affiliation>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</affiliation><affiliation>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</affiliation><affiliation>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</affiliation><affiliation>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</affiliation><affiliation>McGill University Montreal, Quebec, Canada</affiliation></author><author><persName><forename type="first">Mohammad</forename><surname>Shenasa</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Reprint requests: Mohammad Shenasa, MD, PhD, Research Center, Sacré-Coeur Hospital, 5400, Gouin West, Montreal, Quebec, Canada H4J 1C5.</affiliation><affiliation>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</affiliation><affiliation>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</affiliation><affiliation>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</affiliation><affiliation>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</affiliation><affiliation>McGill University Montreal, Quebec, Canada</affiliation></author></analytic><monogr><title level="j">American Heart Journal</title><title level="j" type="abbrev">YMHJ</title><idno type="pISSN">0002-8703</idno><idno type="PII">S0002-8703(00)X0579-0</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1988"></date><biblScope unit="volume">117</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="370">370</biblScope><biblScope unit="page" to="376">376</biblScope></imprint></monogr><idno type="istex">9E7DD0E4258275C9FE85B6F1BE09ECEF9DE59EB6</idno><idno type="DOI">10.1016/0002-8703(89)90781-3</idno><idno type="PII">0002-8703(89)90781-3</idno><idno type="ArticleID">89907813</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1989</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The electrophysiologic effects of intravenous propafenone were studied in 15 consecutive patients with accessory pathways. Thirteen patients had sustained orthodromic supraventricular tachycardia induced during baseline study, and two patients needed isoproterenol to render it sustained. In all except one patient, propafenone, 2 mg/kg given intravenously over a 10-minute period, was successful converting the arrthythmia to sinus rhythm. Atrial fibrillation was inducible in 10 patients before propafenone, but was no longer inducible in seven of these patients after the drug. The HV interval (23 ± 20 to 41 ± 25 msec) and the anterograde (310 ± 96 to 509 ± 145 msec) and retrograde (256 ± 30 to 334 ± 105 msec) effective refractory periods of the bypass tract were all significantly prolonged after the drug. The pacing cycle length that produced conduction block over the bypass tract anterogradely (319 ± 126 to 446 ± 150 msec) and retrogradely (272 ± 25 to 360 ± 97 msec) was also increased. During orthodromic tachycardia, propafenone increased conduction time in both the anterograde and retrograde limbs of the tachycardia. Tachycardia terminated in the retrograde limb in 64% of the patients. We conclude that propafenone is very effective in terminating orthodromic tachycardia when given intravenously and that it should be considered in patients initially seen with atrial fibrillation and short refractory periods.</p></abstract><textClass><keywords scheme="keyword"><list><head>Article category</head><item><term>Clinical investigations</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1988-05-16">Received</change><change when="1988-09-15">Modified</change><change when="1988">Published</change></revisionDesc></teiHeader></istex:fulltextTEI></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla" xml:lang="en"><item-info><jid>YMHJ</jid><aid>89907813</aid><ce:pii>0002-8703(89)90781-3</ce:pii><ce:doi>10.1016/0002-8703(89)90781-3</ce:doi><ce:copyright type="unknown" year="1989"></ce:copyright><ce:doctopics><ce:doctopic><ce:text>Clinical investigations</ce:text></ce:doctopic></ce:doctopics></item-info><head><ce:title>Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome</ce:title><ce:author-group><ce:author><ce:given-name>Marc</ce:given-name><ce:surname>Dubuc</ce:surname><ce:degrees>MD</ce:degrees><ce:cross-ref refid="AFF1"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF2"><ce:sup loc="post">b</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF3"><ce:sup loc="post">c</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF4"><ce:sup loc="post">d</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Teresa</ce:given-name><ce:surname>Kus</ce:surname><ce:degrees>MD, PhD</ce:degrees><ce:cross-ref refid="AFF1"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF2"><ce:sup loc="post">b</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF3"><ce:sup loc="post">c</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF4"><ce:sup loc="post">d</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF5"><ce:sup loc="post">e</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Maria Aurora</ce:given-name><ce:surname>Campa</ce:surname><ce:degrees>MD</ce:degrees><ce:cross-ref refid="AFF1"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF2"><ce:sup loc="post">b</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF3"><ce:sup loc="post">c</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF4"><ce:sup loc="post">d</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF5"><ce:sup loc="post">e</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Chantal</ce:given-name><ce:surname>Lambert</ce:surname><ce:degrees>PhD</ce:degrees><ce:cross-ref refid="AFF1"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF2"><ce:sup loc="post">b</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF3"><ce:sup loc="post">c</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF4"><ce:sup loc="post">d</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF5"><ce:sup loc="post">e</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Michael</ce:given-name><ce:surname>Rosengarten</ce:surname><ce:degrees>MD</ce:degrees><ce:cross-ref refid="AFF1"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF2"><ce:sup loc="post">b</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF3"><ce:sup loc="post">c</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF4"><ce:sup loc="post">d</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF5"><ce:sup loc="post">e</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Mohammad</ce:given-name><ce:surname>Shenasa</ce:surname><ce:degrees>MD, PhD</ce:degrees><ce:cross-ref refid="COR1"><ce:sup loc="post">∗</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF1"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF2"><ce:sup loc="post">b</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF3"><ce:sup loc="post">c</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF4"><ce:sup loc="post">d</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF5"><ce:sup loc="post">e</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="AFF1"><ce:label>a</ce:label><ce:textfn>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>b</ce:label><ce:textfn>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</ce:textfn></ce:affiliation><ce:affiliation id="AFF3"><ce:label>c</ce:label><ce:textfn>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</ce:textfn></ce:affiliation><ce:affiliation id="AFF4"><ce:label>d</ce:label><ce:textfn>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</ce:textfn></ce:affiliation><ce:affiliation id="AFF5"><ce:label>e</ce:label><ce:textfn>McGill University Montreal, Quebec, Canada</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>∗</ce:label><ce:text>Reprint requests: Mohammad Shenasa, MD, PhD, Research Center, Sacré-Coeur Hospital, 5400, Gouin West, Montreal, Quebec, Canada H4J 1C5.</ce:text></ce:correspondence></ce:author-group><ce:date-received day="16" month="5" year="1988"></ce:date-received><ce:date-revised day="15" month="9" year="1988"></ce:date-revised><ce:abstract class="author"><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para view="all" id="simple-para.0010">The electrophysiologic effects of intravenous propafenone were studied in 15 consecutive patients with accessory pathways. Thirteen patients had sustained orthodromic supraventricular tachycardia induced during baseline study, and two patients needed isoproterenol to render it sustained. In all except one patient, propafenone, 2 mg/kg given intravenously over a 10-minute period, was successful converting the arrthythmia to sinus rhythm. Atrial fibrillation was inducible in 10 patients before propafenone, but was no longer inducible in seven of these patients after the drug. The HV interval (23 ± 20 to 41 ± 25 msec) and the anterograde (310 ± 96 to 509 ± 145 msec) and retrograde (256 ± 30 to 334 ± 105 msec) effective refractory periods of the bypass tract were all significantly prolonged after the drug. The pacing cycle length that produced conduction block over the bypass tract anterogradely (319 ± 126 to 446 ± 150 msec) and retrogradely (272 ± 25 to 360 ± 97 msec) was also increased. During orthodromic tachycardia, propafenone increased conduction time in both the anterograde and retrograde limbs of the tachycardia. Tachycardia terminated in the retrograde limb in 64% of the patients. We conclude that propafenone is very effective in terminating orthodromic tachycardia when given intravenously and that it should be considered in patients initially seen with atrial fibrillation and short refractory periods.</ce:simple-para></ce:abstract-sec></ce:abstract></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome</title></titleInfo><name type="personal"><namePart type="given">Marc</namePart><namePart type="family">Dubuc</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</affiliation><affiliation>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</affiliation><affiliation>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</affiliation><affiliation>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Teresa</namePart><namePart type="family">Kus</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</affiliation><affiliation>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</affiliation><affiliation>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</affiliation><affiliation>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</affiliation><affiliation>McGill University Montreal, Quebec, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Maria Aurora</namePart><namePart type="family">Campa</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</affiliation><affiliation>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</affiliation><affiliation>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</affiliation><affiliation>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</affiliation><affiliation>McGill University Montreal, Quebec, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Chantal</namePart><namePart type="family">Lambert</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</affiliation><affiliation>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</affiliation><affiliation>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</affiliation><affiliation>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</affiliation><affiliation>McGill University Montreal, Quebec, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michael</namePart><namePart type="family">Rosengarten</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</affiliation><affiliation>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</affiliation><affiliation>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</affiliation><affiliation>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</affiliation><affiliation>McGill University Montreal, Quebec, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mohammad</namePart><namePart type="family">Shenasa</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Reprint requests: Mohammad Shenasa, MD, PhD, Research Center, Sacré-Coeur Hospital, 5400, Gouin West, Montreal, Quebec, Canada H4J 1C5.</affiliation><affiliation>Clinical Electrophysiology Laboratory, the Department of Medicine, Sacré-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada</affiliation><affiliation>the Department of Pharmacology, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</affiliation><affiliation>the Research Center, Sacré-Coeur Hospital, University of Montreal Montreal, Quebec, Canada</affiliation><affiliation>the Department of Medicine, Montreal General Hospital Montreal, Quebec, Canada</affiliation><affiliation>McGill University Montreal, Quebec, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1988</dateIssued><dateCaptured encoding="w3cdtf">1988-05-16</dateCaptured><dateModified encoding="w3cdtf">1988-09-15</dateModified><copyrightDate encoding="w3cdtf">1989</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">The electrophysiologic effects of intravenous propafenone were studied in 15 consecutive patients with accessory pathways. Thirteen patients had sustained orthodromic supraventricular tachycardia induced during baseline study, and two patients needed isoproterenol to render it sustained. In all except one patient, propafenone, 2 mg/kg given intravenously over a 10-minute period, was successful converting the arrthythmia to sinus rhythm. Atrial fibrillation was inducible in 10 patients before propafenone, but was no longer inducible in seven of these patients after the drug. The HV interval (23 ± 20 to 41 ± 25 msec) and the anterograde (310 ± 96 to 509 ± 145 msec) and retrograde (256 ± 30 to 334 ± 105 msec) effective refractory periods of the bypass tract were all significantly prolonged after the drug. The pacing cycle length that produced conduction block over the bypass tract anterogradely (319 ± 126 to 446 ± 150 msec) and retrogradely (272 ± 25 to 360 ± 97 msec) was also increased. During orthodromic tachycardia, propafenone increased conduction time in both the anterograde and retrograde limbs of the tachycardia. Tachycardia terminated in the retrograde limb in 64% of the patients. We conclude that propafenone is very effective in terminating orthodromic tachycardia when given intravenously and that it should be considered in patients initially seen with atrial fibrillation and short refractory periods.</abstract><subject><genre>Article category</genre><topic>Clinical investigations</topic></subject><relatedItem type="host"><titleInfo><title>American Heart Journal</title></titleInfo><titleInfo type="abbreviated"><title>YMHJ</title></titleInfo><genre type="Journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">198902</dateIssued></originInfo><identifier type="ISSN">0002-8703</identifier><identifier type="PII">S0002-8703(00)X0579-0</identifier><part><date>198902</date><detail type="volume"><number>117</number><caption>vol.</caption></detail><detail type="issue"><number>2</number><caption>no.</caption></detail><extent unit="issue pages"><start>A2</start><end>A16</end></extent><extent unit="issue pages"><start>A23</start></extent><extent unit="issue pages"><start>A30</start></extent><extent unit="issue pages"><start>A35</start><end>A38</end></extent><extent unit="issue pages"><start>275</start><end>508</end></extent><extent unit="pages"><start>370</start><end>376</end></extent></part></relatedItem><identifier type="istex">9E7DD0E4258275C9FE85B6F1BE09ECEF9DE59EB6</identifier><identifier type="DOI">10.1016/0002-8703(89)90781-3</identifier><identifier type="PII">0002-8703(89)90781-3</identifier><identifier type="ArticleID">89907813</identifier><recordInfo><recordContentSource>ELSEVIER</recordContentSource></recordInfo></mods></metadata><enrichments><istex:refBibTEI uri="https://api.istex.fr/document/9E7DD0E4258275C9FE85B6F1BE09ECEF9DE59EB6/enrichments/refBib"><teiHeader></teiHeader><text><front></front><body></body><back><listBibl><biblStruct><analytic></analytic><monogr><title level="j">American Heart Journal REFERENCES</title><imprint><date type="published" when="1989-02"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Propafenone-a new antiarrhythmic drug</title><author><persName><forename type="middle">L</forename><surname>Seipel</surname></persName></author><author><persName><surname>Breithardt</surname></persName></author></analytic><monogr><title level="j">Eur Heart J</title><imprint><biblScope unit="volume">1</biblScope><biblScope unit="page">309</biblScope><date type="published" when="1980"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Electrophysiologic and hemodynamic effects of intravenous propafenone in patients with recurrent ventricular tachycardia</title><author><persName><surname>Shen</surname></persName></author><author><persName><surname>En</surname></persName></author><author><persName><forename type="middle">Rj</forename><surname>Sung</surname></persName></author><author><persName><forename type="middle">F</forename><surname>Morady</surname></persName></author></analytic><monogr><title level="j">J Am Co11 Cardiol</title><imprint><biblScope unit="volume">3</biblScope><biblScope unit="page">1291</biblScope><date type="published" when="1984"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">The multiple modes of action of propafenone</title><author><persName><surname>Dukes</surname></persName></author><author><persName><forename type="first">Vaughan</forename><surname>Id</surname></persName></author><author><persName><forename type="middle">Em</forename><surname>Williams</surname></persName></author></analytic><monogr><title level="j">Eur Heart J</title><imprint><biblScope unit="volume">5</biblScope><biblScope unit="page">115</biblScope><date type="published" when="1984"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Effects of lidocaine on atrioventricular response via the accessory pathway in patients with Wolff-Parkinson-White syndrome</title><author><persName><forename type="first">Gilbert</forename><forename type="middle">M Cj</forename><surname>Akhtar</surname></persName></author><author><persName><surname>Shenasa</surname></persName></author></analytic><monogr><title level="j">Circulation</title><imprint><biblScope unit="volume">71</biblScope><biblScope unit="page">104</biblScope><date type="published" when="1985"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">High-performance liquid chromatographic procedure for the quantification of propafe-none in serum and tissues</title><author><persName><forename type="middle">R</forename><surname>Kannan</surname></persName></author><author><persName><forename type="middle">D</forename><surname>Tidwell</surname></persName></author><author><persName><surname>Singh</surname></persName></author><author><persName><surname>Bn</surname></persName></author></analytic><monogr><title level="j">J Chromatogr</title><imprint><biblScope unit="volume">272</biblScope><biblScope unit="page">428</biblScope><date type="published" when="1983"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">The clinical pharmacol-ogy of propafenone</title><author><persName><forename type="first">Kates</forename><forename type="middle">Na Re</forename><surname>Smith</surname></persName></author><author><persName><surname>Harrison</surname></persName></author><author><persName><surname>Dc</surname></persName></author></analytic><monogr><title level="j">J Electrophysiol</title><imprint><biblScope unit="volume">1</biblScope><biblScope unit="page">517</biblScope><date type="published" when="1987"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Effect of propafenone in the Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up</title><author><persName><forename type="middle">G</forename><surname>Breithardt</surname></persName></author><author><persName><forename type="first">Wiebringhaus</forename><forename type="middle">M E</forename><surname>Borggrefe</surname></persName></author><author><persName><surname>Seipel</surname></persName></author></analytic><monogr><title level="j">Am J Cardiol</title><imprint><biblScope unit="volume">54</biblScope><biblScope unit="page">29</biblScope><date type="published" when="1984"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Intravenous propafenone for termina-tion of reentrant supraventricular tachycardia. A placebo-controlled, randomized, double-blind, crossover study</title><author><persName><surname>Shen En</surname></persName></author><author><persName><forename type="middle">E</forename><surname>Keung</surname></persName></author><author><persName><forename type="middle">E</forename><surname>Huycke</surname></persName></author><author><persName><forename type="middle">Ml</forename><surname>Dohrmann</surname></persName></author><author><persName><forename type="middle">N</forename><surname>Nguyen</surname></persName></author><author><persName><forename type="middle">F</forename><surname>Morady</surname></persName></author><author><persName><surname>Sung</surname></persName></author></analytic><monogr><title level="j">Ann Intern Med</title><imprint><biblScope unit="volume">105</biblScope><biblScope unit="page">655</biblScope><date type="published" when="1986"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Efficacy of propafenone in Wolff-Parkinson-White syn-drome: electrophysiologic findings and long-term follow-up</title><author><persName><surname>Ludmer Pl</surname></persName></author><author><persName><surname>Mcgowan Ne</surname></persName></author><author><persName><forename type="middle">Em</forename><surname>Antman</surname></persName></author><author><persName><surname>Friedman</surname></persName></author></analytic><monogr><title level="j">J Am Co11 Cardiol</title><imprint><biblScope unit="volume">9</biblScope><biblScope unit="page">1357</biblScope><date type="published" when="1987"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Electrophysiological and antiarrhythmic properties of pro-pafenone in isolated cardiac preparations</title><author><persName><forename type="middle">F</forename><surname>Ledda</surname></persName></author><author><persName><forename type="middle">L</forename><surname>Mantelli</surname></persName></author><author><persName><forename type="middle">S</forename><surname>Manzini</surname></persName></author><author><persName><forename type="middle">S</forename><surname>Amerini</surname></persName></author><author><persName><surname>Mugelli</surname></persName></author></analytic><monogr><title level="j">J Cardiovasc Phar-macol</title><imprint><biblScope unit="volume">3</biblScope><biblScope unit="page">1162</biblScope><date type="published" when="1981"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Demonstration of beta-adrenoceptor blockade by propafenone hydrochloride: clini-cal pharmacologic, radioligand binding and adenylate cyclase activation studies</title><author><persName><forename type="middle">Aa</forename><surname>Mcleod</surname></persName></author><author><persName><surname>Stiles Gl</surname></persName></author><author><persName><surname>Shand</surname></persName></author><author><persName><surname>Dg</surname></persName></author></analytic><monogr><title level="j">J Pharmacol Exp Ther</title><imprint><biblScope unit="volume">228</biblScope><biblScope unit="page">461</biblScope><date type="published" when="1984"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Beta-blocking and electrophysiological effects of propafe-none in volunteers</title><author><persName><surname>Muller</surname></persName></author><author><persName><forename type="middle">H</forename><surname>Pelzer</surname></persName></author><author><persName><forename type="middle">G</forename><surname>Greger</surname></persName></author><author><persName><forename type="middle">G</forename><surname>Neugebauer</surname></persName></author><author><persName><surname>Hollmann</surname></persName></author></analytic><monogr><title level="j">Eur J Clin Pharmacol</title><imprint><biblScope unit="volume">25</biblScope><biblScope unit="page">831</biblScope><date type="published" when="1983"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Electrophysiologic and hemody-namic effects of intravenous propafenone in patients with recurrent ventricular tachycardia</title><author><persName><forename type="first">En</forename><surname>Shen</surname></persName></author><author><persName><forename type="first">Rj</forename><surname>Suns</surname></persName></author><author><persName><forename type="first">F</forename><surname>Moradv</surname></persName></author><author><persName><forename type="first">Ab</forename><surname>Schwartz</surname></persName></author><author><persName><surname>Scheinman Mm</surname></persName></author><author><persName><forename type="first">Ly</forename><surname>Dicarlo</surname></persName></author><author><persName><surname>Shapiro</surname></persName></author></analytic><monogr><title level="j">J Am Co11 Cardiol</title><imprint><biblScope unit="volume">3</biblScope><biblScope unit="page">1291</biblScope><date type="published" when="1984"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Double-blind study of intravenous propafenone for paroxysmal supraventricular reentrant tachycardia</title><author><persName><surname>Hammill</surname></persName></author><author><persName><surname>Sc</surname></persName></author><author><persName><surname>Mclaran</surname></persName></author><author><persName><surname>Cj</surname></persName></author><author><persName><surname>Wood</surname></persName></author><author><persName><surname>Dl</surname></persName></author><author><persName><forename type="middle">Mj</forename><surname>Osborn</surname></persName></author><author><persName><forename type="middle">Bj</forename><surname>Gersh</surname></persName></author><author><persName><surname>Holmes</surname></persName></author></analytic><monogr><title level="j">J Am Co11 Cardiol</title><imprint><biblScope unit="volume">9</biblScope><biblScope unit="page">1364</biblScope><date type="published" when="1987"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Effect of drugs in the Wolff-Parkinson-White syn-drome. Importance of initial length of effective refractory period of the accessory pathway</title><author><persName><forename type="first">Wellens</forename><forename type="middle">Hjj</forename><surname>Bar Fw</surname></persName></author><author><persName><surname>Dassen Wrm</surname></persName></author><author><persName><forename type="middle">P</forename><surname>Brugada</surname></persName></author><author><persName><surname>Vanagt Ej</surname></persName></author><author><persName><surname>Farm</surname></persName></author></analytic><monogr><title level="j">Am J Cardiol</title><imprint><biblScope unit="volume">46</biblScope><biblScope unit="page">665</biblScope><date type="published" when="1980"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Ventricular fibrillation in the Wolff-Parkinson-White syndrome</title><author><persName><surname>Klein Gh</surname></persName></author><author><persName><forename type="middle">Tm</forename><surname>Bashore</surname></persName></author><author><persName><forename type="middle">Td</forename><surname>Sellers</surname></persName></author><author><persName><surname>Pritchett</surname></persName></author><author><persName><surname>Elc</surname></persName></author><author><persName><forename type="middle">Wm</forename><surname>Smith</surname></persName></author><author><persName><surname>Gallagher</surname></persName></author><author><persName><surname>Jj</surname></persName></author></analytic><monogr><title level="j">N Engl J Med</title><imprint><biblScope unit="volume">301</biblScope><biblScope unit="page">1080</biblScope><date type="published" when="1979"></date></imprint></monogr></biblStruct></listBibl></back></text></istex:refBibTEI></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002215 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002215 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:9E7DD0E4258275C9FE85B6F1BE09ECEF9DE59EB6
|texte= Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome
}}
| This area was generated with Dilib version V0.6.23. |  |